Outcomes from the I‐SPY trial demonstrate that patient outcomes can substantially differ based on molecular tumor markers; in the trial, the majority of patients were clinical N1/pathologic N1 (cN1/pN1), and HR+, HER2− patients experienced the lowest rate of pCR after NAC (9% for HR+, 33% for HR+, HER2+, 35% for triple-negative, and 58% for HR−, HER2+) [18]. Here, ERBB2 is linked to neoplasm.